George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.82
Bid: 3.70
Ask: 3.94
Change: 0.01 (0.26%)
Spread: 0.24 (6.486%)
Open: 3.81
High: 0.00
Low: 0.00
Prev. Close: 3.81
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on sugarcane in Brazil

30 Jul 2018 07:00

RNS Number : 0790W
Plant Health Care PLC
30 July 2018
 

 

 

30 July 2018

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

 

Update on sugarcane in Brazil

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, provides the following update on Harpin αβ launch in Brazil.

 

 

Highlights

- Harpin αβ applied in sugarcane in Brazil; demonstration plot yield increase of 20% or more.

- Harpin αβ was launched in Brazil sugarcane in February 2018 through Coplacana under the brand name H2Copla. Grower feedback has been strong.

- Since the launch of H2Copla in February 2018, the product has generated revenue of $400k. The Company expects to generate at least as much revenue from H2Copla in the second half of 2018.

- The Company is now planning for the launch of Harpin αβ in coffee, which has similar potential to sugarcane.

 

With 10 million hectares planted, Brazil sugarcane is an important target for Plant Health Care. The Company has been developing Harpin αβ for use in this crop. Trials have been conducted in both ratoon cane (i.e. cane which grows back after harvest) and newly planted cane (normal practice is to take five crops from ratton cane, then plant again). Trials conducted on behalf of the Company in 2018 showed that single applications of a low dose (100 g per Ha) at six to eight weeks after harvest, significantly increased the yield of ratoon cane (10-29%) in ratoon cane. Moreover, it is possible that the ratoon crop may be extended from five to six years, which is a material cost reduction, especially when sugar prices are low. Trials also indicated that newly planted cane responds well to applications of Harpin αβ.

 

Based on these promising results, as announced on 16 July 2018, the Company launched a Harpin αβ product with Coplacana, a leading sugarcane co-operative in Brazil, for their exclusive use of the H2Copla brand in sugarcane. Coplacana services more than 70% of the sugarcane hectares in Sao Paolo state, where more than 5 million hectares of the crop are grown. Demonstration trials with Coplacana have shown impressive results, with an average yield increase of over 20%.

 

H2Copla was launched in February 2018 and the product has received very positive grower feedback. The launch quantities have been largely sold and the Company expects to make further sales during the second half of 2018. We confidently expect sales in Brazilian sugarcane to build in the second half of 2018 and over the coming years.

 

Arnaldo Bortoletto, President of Coplacana, said "We continue to have excellent field results with H2Copla, with good grower feedback and we expect strong demand for H2Copla in the second half of 2018".

 

Jeff Tweedy, Commercial Head, Americas for Plant Health Care, said: "We are very encouraged by the support we are receiving from Coplacana in promoting H2Copla in the field and have high expectations for future sales. The Company is now developing Harpin αβ in other crops. In 2017/18, we had most encouraging preliminary results in coffee, with both yield and quality improvements. We are now examining routes to market for Harpin αβ in this crop, with a view to launching for the 2019-2020 growing season. We see coffee as being at least as valuable a crop for the Company as sugarcane."

 

 

 

For further information, please contact:

 

Plant Health Care plc

Chris Richards, Executive Chairman and Interim CEO Tel: +1 919 926 1600

Jeffrey Tweedy, Commercial Head, Americas

 

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke Tel: +44 (0) 20 3100 2000

 

Arden Partners plc - Joint BrokerJohn Llewellyn-Lloyd / Dan Gee-Summons Tel: +44 (0) 20 7614 5900

 

IFC Advisory - Financial PR

Graham Herring / Miles Nolan / Zach Cohen Tel: +44 (0) 20 3934 6633

 

 

Company website: www.planthealthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBIGDRCSDBGIR
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.